Show simple item record

dc.identifier.urihttp://hdl.handle.net/11401/77006
dc.description.sponsorshipThis work is sponsored by the Stony Brook University Graduate School in compliance with the requirements for completion of degree.en_US
dc.formatMonograph
dc.format.mediumElectronic Resourceen_US
dc.language.isoen_US
dc.publisherThe Graduate School, Stony Brook University: Stony Brook, NY.
dc.typeDissertation
dcterms.abstractParkinson’s disease (PD) is a neurodegenerative disorder involving the basal ganglia that results in a host of motor and cognitive deficits. The hallmark motor symptoms of the disease, such as tremor and rigidity, are generally well-treated with medications that boost the neurotransmitter dopamine. However, whether dopamine-replacement therapy restores cognitive function is under intense debate. While some studies have shown cognitive benefits for individuals taking dopaminergic medications, others have reported null findings or even exacerbated cognitive impairment for individuals in the medicated state. Current theories generally attribute the variety of findings to task differences and the uneven pattern of PD neuropathology across the basal ganglia. However, few studies consider how disease duration may interact with medication status to produce changes in cognitive function. This is an important consideration, as profound loss of dopamine-containing cells in the advanced stages of PD renders dopaminergic medication relatively ineffective. Here, in a meta-analysis it is evident that disease duration modulates cognitive function for individuals on dopaminergic medication. In a functional magnetic resonance imaging study of the stop-signal task (SST), we find that early-stage individuals have a restoration of response inhibition behavior with dopaminergic medication, in contrast to previous studies reporting null effects in more advanced individuals with PD. Bayesian computational modeling of SST performance identified a possible mechanism by which dopaminergic medication improves response inhibition in early-stage PD. Specifically, compared to a 12-hour washout “off’ medication state, individuals in the “on†state showed improvements in their ability to make behavioral adjustments across trials of the task. This manifested itself in increased brain activations to the anticipation of salient events, and decreased activations to surprise in lateral and medial frontoparietal regions. Together, these findings highlight the importance of disease duration when considering medication effects on cognitive function in PD. They also identify a potential novel mechanism by which dopamine supports frontoparietal cognitive control, centered on trial-to-trial learning, behavioral adjustment and increased neural signatures of anticipation.
dcterms.available2017-09-20T16:51:38Z
dcterms.contributorLeung, Hoi-Chungen_US
dcterms.contributorLuhmann, Christianen_US
dcterms.contributorCanli, Turhanen_US
dcterms.contributorLi, Chiang-shan R.en_US
dcterms.creatorManza, Pete
dcterms.dateAccepted2017-09-20T16:51:38Z
dcterms.dateSubmitted2017-09-20T16:51:38Z
dcterms.descriptionDepartment of Biopsychologyen_US
dcterms.extent86 pg.en_US
dcterms.formatApplication/PDFen_US
dcterms.formatMonograph
dcterms.identifierhttp://hdl.handle.net/11401/77006
dcterms.issued2016-12-01
dcterms.languageen_US
dcterms.provenanceMade available in DSpace on 2017-09-20T16:51:38Z (GMT). No. of bitstreams: 1 Manza_grad.sunysb_0771E_13111.pdf: 2196175 bytes, checksum: 72dc35581bac5ee12185a6a298eadd40 (MD5) Previous issue date: 1en
dcterms.publisherThe Graduate School, Stony Brook University: Stony Brook, NY.
dcterms.subjectNeurosciences -- Cognitive psychology -- Psychobiology
dcterms.subjectbasal ganglia, dopamine, fMRI, levodopa, proactive control, response inhibition
dcterms.titleNeurocomputation, dopaminergic treatment, and cognitive control in early-stage Parkinson's Disease
dcterms.typeDissertation


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record